Nucleos（t）ide模拟治疗患者中乙型肝炎病毒肝细胞癌的临床特

StephenW

Infect Agent Cancer. 2020 Feb 4;15:8. doi: 10.1186/s13027-020-0277-y. eCollection 2020.
Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy.
Liu L1.
Author information

1
    Infectious disease department, Hunan provincial peoples ~ hospital (The first affiliated hospital of Hunan Normal university), Hunan province, Changsha, 410000 China.

Abstract
Background:

The clinical manifestation of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) varies significantly between patients treated with or without nucleos(t) ide analog (NUC) therapy. To have a better understanding of HCC with HBV, we compared the clinical features of patients with HCC receiving or not receiving NUC therapy.
Methods:

We retrospectively reviewed the medical records of 76 patients with HBV-caused HCC who received treatment at the Hunan Provincial Peoples' Hospital starting from January 1, 2008 to December 31, 2017. They were categorized into two groups, namely, NUC group and non-NUC group, based on whether they had received NUC therapy or not.
Results:

The percentage of liver pain (36.36% vs. 79.07%; p < 0.05) and appetite loss (30.30% vs. 70.27%; p < 0.05) in the NUC group was lower than that in the non-NUC group. We observed a similar trend for the percentage of undetectable HBV-DNA (11.63% vs. 63.64%; p < 0.05) and normal ALT (25.58% vs. 75.76%; p < 0.05) between non-NUC and NUC groups. There were no significant differences between the two groups with respect to TBiL (p = 0.370) and ALB (p = 0.475). The same trend was observed for the proportion of HBeAg negative (p = 0.719) and AFP ≤ 14.65 ng/mL (p = 0.199) in both groups. Single tumor nodule was more common in the NUC group compared to the non-NUC group (66.67% vs. 6.98%; p < 0.05). An opposite trend was observed for portal vein invasion (18.18% vs. 79.07%; p < 0.05) and metastasis (0% vs. 44.19%; p < 0.05).
Conclusions:

Nucleos(t) ide analog therapy exerts a significant impact on the clinical and radiological characteristics of hepatocellular carcinoma with HBV. Patients receiving nucleos(t) ide analog therapy were found to have milder symptoms and fewer radiographic findings.

© The Author(s). 2020.
KEYWORDS:

HBV; Hepatocellular carcinoma; Nucleos(t) ide analogs

PMID:
    32042307
PMCID:
    PMC7001249
DOI:
    10.1186/s13027-020-0277-y

StephenW

感染剂癌症。 2020年2月4日； 15：8。Doi：10.1186 / s13027-020-0277-y。 ECollection 2020。
Nucleos（t）ide模拟治疗患者中乙型肝炎病毒肝细胞癌的临床特征。
刘丽1。
作者信息

1个
湖南省湖南省人民医院传染病科（湖南师范大学第一附属医院），长沙，中国410000。

抽象
背景：

接受或不接受核苷酸类似物（NUC）治疗的患者中，乙型肝炎病毒（HBV）引起的肝细胞癌（HCC）的临床表现差异很大。为了更好地了解HCC和HBV，我们比较了接受或不接受NUC治疗的HCC患者的临床特征。
方法：

我们回顾性分析了从2008年1月1日至2017年12月31日在湖南省人民医院接受治疗的76例HBV引起的HCC患者的病历。他们分为NUC组和非NUC组。 NUC组基于他们是否接受过NUC治疗。
结果：

NUC组的肝痛百分比（36.36％vs. 79.07％； p <0.05）和食欲不振（30.30％vs 70.27％； p <0.05）低于非NUC组。在非NUC组和NUC组之间，未检出HBV-DNA的百分比（11.63％vs. 63.64％； p <0.05）和正常ALT（25.58％vs. 75.76％； p <0.05）观察到相似的趋势。两组之间的TBiL（p = 0.370）和ALB（p = 0.475）没有显着差异。两组的HBeAg阴性比例（p = 0.719）和AFP≤14.65 ng / mL（p = 0.199）观察到相同的趋势。与非NUC组相比，NUC组中单个肿瘤结节更为常见（66.67％对6.98％； p <0.05）。观察到相反的趋势，门静脉侵犯（18.18％vs. 79.07％； p <0.05）和转移（0％vs. 44.19％； p <0.05）。
结论：

核苷类似疗法对HBV肝细胞癌的临床和放射学特征有重大影响。发现接受核苷类似物治疗的患者症状较轻，影像学检查较少。

©作者。 2020年。
关键字：

乙肝病毒肝细胞癌；核（t）ide类似物

PMID：
32042307
PMCID：
PMC7001249
DOI：
10.1186 / s13027-020-0277-y

StephenW

https://infectagentscancer.biome ... 6/s13027-020-0277-y